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Abstract
Recently, the USA FDA has made a labeling change to the drug information contained in
carbamazepine. Owing to recent data implicating the HLA allele B*1502 as a marker for
carbamazepine-induced Stevens–Johnson syndrome and toxic epidermal necrolysis in Han Chinese,
the FDA recommends genotyping all Asians for the allele. This allele is seen in high frequency in
many Asian populations other than Han Chinese, but there are few data on whether the allele is a
marker for this severe outcome in anyone other than Han Chinese. In fact, the association has not
been found in Caucasian patients. We review the data that prompted this recommendation, list data
for other ethnic groups, both Asian and non-Asian, and briefly discuss the implication of this
recommendation for clinical practice.
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The US FDA has been conducting systematic evaluations of pharmacogenetic predictors for
previously approved medications. The past 4 years have seen pharmacogenetic information
included into the prescribing information (so-called ‘package insert’) for 6-mercaptopurine,
azathioprine, irinotecan and warfarin. The FDA Committee on Clinical Pharmacology has
recommended similar changes for tamoxifen. On 12 December 2007, the FDA released a
warning to health professionals and patients that serious and potentially fatal skin reactions
may occur with the administration of carbamazepine in patients positive for the HLA-
B*1502 allele [101]. In addition, the FDA recommended genetic screening for patients of Asian
ancestry before initiation of carbamazepine therapy. We review the data upon which this
decision was made and offer insight into some of the factors limiting these data.
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Carbamazepine is an important treatment for seizure disorders, bipolar disorder, trigeminal
neuralgia and chronic pain. However, carbamazepine is also associated with hypersensitivity
reactions that range from benign urticaria to life-threatening cutaneous disorders, including
Stevens–Johnson syndrome (SJS) and toxic epidermal necrolysis (TEN) [1–3]. The latter two
disorders carry a mortality that can be as high as 30% and require early diagnosis, with prompt
withdrawal of all suspected potential causative drugs. While SJS and TEN occupy the ends of
a continuous clinical spectrum, SJS, overlap SJS/TEN, and TEN are three distinct diagnoses.
Each presents with erythematous or purpuric macules or flat atypical targets with less than
10% (SJS), 10−30% (overlap SJS/TEN) and greater than 30% (TEN) detachment of body
surface area (BSA). A similar condition, TEN without spots, presents with epidermal
detachment greater than 10% BSA, but no macular lesions [4]. Gastrointestinal and
tracheobronchial epithelial involvement may lead to increased mortality, while immunologic
and epidermal disruption often lead to infection and sepsis [5]. Treatment of these conditions
requires admission to an intensive care unit or burn center, but no single treatment modality
has been shown to be clearly most effective [6]. Pharmacologic therapies aimed at altering the
immune response, such as corticosteroids, ciclosporin and intravenous immunoglobulin, are
most often employed [7].
Increased risk with HLA-B*1502 allele
Chung et al. were the first to identify an association between carbamazepine-induced SJS/TEN
and HLA-B*1502 [8]. This case–control analysis included 44 (out of 73 reported) cases of
carbamazepine-induced SJS/TEN (carbamazepine-SJS/TEN) in Taiwan between 1996 and
2003 and compared genotyping data for 157 SNPs in CYP genes as well alleles of the HLA-
A, -B, -C and DRB1 genes. The patients were all Han Chinese living in Taiwan during this
time, while 101 carbamazepine-tolerant (at least 3 months of use with no adverse reactions)
and 93 samples of randomly selected, biobanked DNA from normal, healthy individuals served
as study controls. The authors reported that all 44 (100%) were positive for the HLA-B*1502
allele, while only three (3%) carbamazepine-tolerant and eight (8.6%) normal controls had the
allele. The odds ratio for developing carbamazepine-induced SJS/TEN if positive for HLA-
B*1502 was 2504 (95% CI: 126−49,522) and a corrected p-value (pc) of 3.13 × 10−21.
In 2006, these authors added 16 new cases, all Chinese descent, with carbamazepine-SJS/TEN
and reported that 59 out of 60 were positive for the HLA-B*1502 allele, while the one subject
without HLA-B*1502 was positive for another B15 allele, HLA-B*1558 [9]. Reported odds
ratio and pc were 1357 (95% CI: 193.4−8838.3) and 1.6 × 10−21, respectively. In addition, a
report has been published by Man et al. that highlights, among others, four Han Chinese patients
who had SJS/TEN when exposed to carbamazepine. All four were positive for HLA-B*1502
[10].
HLA-B*1502 as a screening test in Han Chinese
These data suggest that Han Chinese who have the HLA-B*1502 allele are at a much increased
risk of developing SJS/TEN when exposed to carbamazepine. Assuming a 0.25% incidence of
carbamazepine-SJS/TEN in newly prescribed carbamazepine patients in Taiwan [9] and a 3%
false-positive rate for HLA-B*1502, the estimated performance would be 98.3% sensitivity,
97% specificity, 7.7% positive predictive value and 100% negative predictive value. Given the
fact that one would detect 98.3% of the one case in every 400 people, the number needed to
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screen is 407 people, with subsequent carbamazepine avoidance, to prevent one case of SJS/
TEN. As they were obtained from a case–control study, all of these data are estimated values,
not actual ones, although it is probably not practical to expect observational data for such a
rare outcome as SJS/TEN.
Testing in non-Chinese Asians
Although no published data have yet confirmed such a strong correlation of HLA-B*1502 and
carbamazepine-SJS/TEN in non-Chinese Asians, the relatively high incidence of HLA-
B*1502 in many Asian populations has resulted in the FDA's decision to recommend testing
for all Asians. In India, several reports have implicated carbamazepine as among the most
common causes for SJS/TEN [3,11,12]. Similarly, studies in Singapore and Malaysia have
reported carbamazepine as the most common cause of SJS/TEN, accounting for 27.7 and 35.7%
of cases, respectively [13,14]. However, Thailand has reported much lower proportions of SJS/
TEN being caused by carbamazepine [15]. Prevalence of the HLA-B*1502 allele in Asian
populations is also much higher than in Caucasian and African populations (Table 1).
Non-Asian concerns
In Caucasians, at least two studies have failed to show a correlation between HLA-B*1502
status and carbamazepine-SJS/TEN [16,17]. In the first study, the authors report that none of
the 56 patients with carbamazepine-associated cutaneous reactions had HLA-B*1502 [16].
However, there were only two cases of SJS/TEN (one SJS, one TEN), with the remaining
patients having other classifications of cutaneous reaction. This is important, as the Taiwanese
study only found a strong genetic correlation in carbamazepine-SJS/TEN and no other
carbamazepine-induced severe cutaneous reactions [9]. Therefore, this study may only
highlight the relative rarity of both the allele and outcome in question. The second study
investigated 12 cases of carbamazepine-SJS/TEN taken from a larger European study on SJS/
TEN, the European Registry of Severe Cutaneous Reactions (RegisSCAR) [17]. Only four of
these were positive for the HLA-B*1502 allele, but all four of them had Asian ancestry. These
authors concluded that perhaps ethnicity has an important effect on the penetrance of the allele
in question. Based on the lack of evidence and relative infrequency of HLA-B*1502 in those
with non-Asian ancestry, genotypic screening for HLA-B*1502 in non-Asian patients is of little
apparent value.
Class effect or drug specific?
Oxacarbazepine has a highly similar chemical structure to carbamazepine and is used to treat
many of the same clinical indications. However, whether there is a similar genetic
predisposition to SJS/TEN is unclear. Although cross-reactivity for skin reactions from the
two drugs has been reported to occur in one in four patients, a small case series (n = 3)
demonstrated the need to proceed cautiously when using oxacarbazepine for already
carbamazepine-intolerant patients [18]. In three consecutive patients, all had skin reactions
with exposure to a low dose of oxacarbazepine. For this reason, oxacarbazepine is not likely
to be a good choice when prescribing for patients who are HLA-B*1502 positive. Geno-typing
before primary oxacarbazepine treatment has neither been recommended nor studied.
Conclusion
Current recommendations for genotyping all Asian patients are based on a strong correlation
between HLA-B*1502 and carbamazepine-SJS/TEN in Han Chinese. Importantly, there is a
wide access to high-resolution HLA typing within the USA and other developed countries. The
relative lack of information regarding the correlation in both Asian population groups who
have a high frequency of HLA-B*1502 should prompt further investigation. Given the
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availability of other effective medications for similar indications, it is likely prudent to avoid
carbamazepine when patients have tested positive, despite the low estimated positive predictive
value of the test.
Future perspective
Further study in this field should take a three-pronged approach. First, robust clinical studies
that include large cohorts of carbamazepine-exposed patients are needed, particularly in non-
Asian patient populations. This will be possible through the creation of patient drug registries.
Second, immunological investigation, which is currently underdeveloped, detailing the
molecular mechanisms responsible for precipitating severe skin reactions would pave the way
for novel treatments or preventive measures for these serious, debilitating clinical disorders.
There has been little more than theoretical explanation in this field as yet. Moreover, these are
complex problems with multifactorial causes; therefore, our investigation should be wide-
ranging and thorough. Third, genetic risk factors for hypersensitivity reactions and other life-
threatening conditions related to a variety of drugs should be investigated. Other drugs and
alleles have already been implicated, including abacavir and allopurinol, and more should be
assessed [19,20].
Executive summary
• Carbamazepine-induced Stevens–Johnson syndrome and toxic epidermal
necrolysis is an uncommon, but severe, occurrence.
• Recent recommendations by the US FDA include genotyping for all Asian
carbamazepine patients before therapy.
• The HLA-B*1502 allele is highly associated with the outcome of carbamazepine-
induced Stevens–Johnson syndrome and toxic epidermal necrolysis.
• This association has been found mostly in the Han Chinese, but not in Caucasian
patients.
• The recommendation for testing other Asians groups is the relatively high
incidence of HLA-B*1502.
• Future directions in this field include prospective screening studies and more
genotyping of patients who have already experienced the outcome.
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Table 1
HLA-B*1502 frequencies in major populations.
Continent Population/ethnicity Allele frequency (%) n




Native American 0 235
Asia Korean 0.5 200





India Mumbai Marathas 1 72
India North Hindi 2 91
India Khandesh Pawra 6 50
Data obtained from [102,103].
102Middleton D: Allele Frequencies in Worldwide Populations www.allelefrequencies.net
103International Histocompatibility Working Group www.ihwg.org
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